TEZSPIRE shows positive Phase III CROSSING results in eosinophilic esophagitis
FROM THE WIRE · FINANCE.YAHOO.COM
First and only biologic therapy to achieve statistically significant and clinically meaningful histologic remission and symptom improvements at week 24 that were sustained through week 52 vs. placebo TEZSPIRE attained statistically significant total endoscopic remission with…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishPositive Phase III data for a key AstraZeneca drug may support the share price.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01The CROSSING trial met its statistically significant co-primary endpoints.
- 02Histologic remission was sustained through week 52 versus placebo.
- 03Total endoscopic remission was also statistically significant versus placebo at week 52.
NEWS IMPACT AND MARKET REACTIONChange from the reference price
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets